Bioverativ develops and commercializes drug therapies for the treatment of hemophilia and other blood disorders... Read more
Bioverativ develops and commercializes drug therapies for the treatment of hemophilia and other blood disorders... Read more
News
Jun 12, 2020
European Biotechnology
Bioverativ: Abzena's partner True North Therapeutics subject of US$825m take-over
Jun 14, 2019
Invest Advocate
Bioverativ: SEC Charges Swiss Resident in Insider Trading Case Involving Bioverativ Acquisition
Dec 03, 2018
BioPortfolio
Bioverativ: BIVV001 Phase 12a Data Presented at ASH Underscore Potential for Once Weekly Dosing with Sustained High Factor Levels in Hemophilia A
Dec 02, 2018
PharmiWeb
Bioverativ: At ASH, Extended Half-life Therapies Elocta® and Alprolix® Demonstrate Proven Efficacy and Well-characterised Safety Over Four Years
Nov 19, 2018
Pharamceutical Technology
Bioverativ: Jefferies Healthcare Conference 2018: SOBI bets on the haemophilia market
Nov 12, 2018
BioPortfolio
Bioverativ: Bioverativ Inc BIVV Medical Equipment Deals and Alliances Profile Report Updated 16102018 Prices from USD $250
Nov 01, 2018
Business Wire
Press Release: Bioverativ : New Data at ASH Showcase Bioverativ's Commitment to Transforming Care for People with Hemophilia and Other Rare Blood Disorders
Aug 31, 2018
BioPortfolio
Bioverativ: Bioverativ Inc BIVV Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 16042018 Prices from USD $250
Aug 15, 2018
PMLiVE
Bioverativ: Rogerio Vivaldi leaves Bioverativ buyout to head up Sigilon
Jun 27, 2018
Bioverativ Youtube Channel
Bioverativ posted a video "Bioverativ at the 2018 New England Hemophilia Association Walk" on YOUTUBE
Bioverativ Inc. Competitors
1
2
3
4
5
6
7
8
9
10